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CHAPTER 1. INTRODUCTION 
1.1 Preliminaries 
In medicine it is often desired to classify a patient either as healthy or diseased. 
Sometimes this classification can be done exax:tly. However, exactness is usually 
highly expensive or may require an undesirable procedure, e.g., biopsy or surgery. In 
this study we will deal with diagnostic tests or diagnostic markers (DMs) which assign 
a continuous value for each patient. As a convention we will assume that the higher 
value of a DM is associated with the presence of a disease. In other words, using 
preassigned or given cutoff points, a patient with a marker vcdue exceeding the cutoff 
is called diseased, otherwise is called healthy. I will use the terms case and control 
instead of diseased and healthy to show that generalization of the above classification 
may be achieved with other systems which produce a dichotomous outcome. DMs are 
most of the time easy to implement and substantially cheaper than exact methods. 
However, they are not error free. There are two errors that can be made by using a 
DM, classifying a case as a control, or classifying a control cis a case. In biostatisticcd 
literature the probability that a DM classifies a case as a control is called false negative 
ratio and probability that a DM classifies a control as a case is false positive ratio 
(Metz, 1978). Intuitive definitions for true negative ratio and true positive ratio 
follow. However, often the terms specificity and sensitivity are used. Specificity is 
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the probability that a control is correctly identified by a DM and sensitivity is the 
probability of correctly claissifying a case by a DM. 
In this work, we will adapt the definitions of sensitivity and specificity of a 
DM for repeated markers (the case where several values obtciined from one subject as 
contrast to single marker studies where one value per subject is available) and develop 
theoretical background to compare sensitivities of two DMs at a fixed specificity. 
This will generalize work done for the single (non-repeated) marker case presented in 
Greenhouse and Mantel (1950). 
1.2 Repeated Markers and Comparison of Diagnostic Markers 
It is often the case that when patients are diagnosed with an illness, they return 
for follow-up visits. For example, the North Central Cancer Treatment Group and 
Mayo Clinic completed studying patients who presented with breast cancer and had 
a lesion which was measurable or evaluable and could be followed for progression 
(growth of the lesion). As part of the follow-up, the patients were to report for a 
physical examination on a regular schedule (every three to five weeks). If we assume 
that the result of the physical examination, progression or not, would define true 
positive or true negative, then DMs of interest applied to the patients at the follow-
up visits might be useful as a surrogate for the physical examination. 
Currently, the most common method for evaluating repeated markers is to use 
a time-dependent Cox model (Cox, 1972 and Kalbfleisch and Prentice, 1980, and 
also see section 4.2.1). However, this method is not adequate to answer the question 
of whether the markers are clinically useful, i.e., the method does not measure the 
diagnostic ability of a marker. We prefer to have a method in terms of specificity 
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and sensitivity and will present an example illustrating why we prefer this method. 
Hence, in chapter two, we first propose a definition of specificity and sensitivity and 
describe their nonpaxametric estimators. Then, we derive the theory required to 
obtain confidence intervals for the specificity and sensitivity of a marker and define 
an asymptotically normal statistic for comparing the sensitivities of two markers at 
a fixed specificity. In chapter three, we will study the properties of our procedures 
using simulations to summarize the finite sample properties. In chapter four, we will 
use several of our methods to provide an analysis of the breast cancer data. Time 
dependent Cox model results for the saune data will be presented in this chapter. 
In chapter five, we will present simulation results for compeiring a weighted aver­
age of sensitivities across aJl specificities. These simulations indicate that it will 
be possible to determine the properties of a statistic used to compare the average 
sensitivitity for two markers. This would generalize work by DeLong, DeLong, and 
Clarke-Pearson(1988) and Wieand, Gail, James and James (1989). Graphically, this 
approach is similar to comparing the areas under two receiver operating characteristic 
(ROC) curves, a concept also discussed in Chapter 5. 
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CHAPTER 2. PROPOSED METHODS 
2.1 Preliminaries 
We have several goals which we will address in this chapter: 
1. Give a definition of sensitivity and specificity when markers are repeated, 
2. Obtain confidence intervals for sensitivity and specificity, and 
3. A method to compare two or more markers using sensitivity ajid specificity. 
2.2 Definitions and Examples 
In this section, we will provide definitions and give examples. To develop our 
theory, our goal is to compare two markers in terms of their usefulness as a re­
placement for a clinical examination in assessing disease progression. Thus the gold 
standard will be the diagnosis following a clinical examination (progression or no 
progression). We now begin the process of defining a statistic that will allow us to 
compare sensitivities at a fixed specificity. 
Before formally defining the statistic, it will be helpful to introduce the following 
example. Suppose that a cancer patient returned for six visits after entering a study, 
and values were obtained for the monoclonal antibody carcionoembryonic antigen 
(CEA) at each visit and these values were 3.0,1.6, 2.3, 1.8,1.7 and 2.8. Let's assume 
that the CEA will be considered positive, i.e., predictive of cancer if the CEA is > 2. 
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In addition, assume that the patient recurred at the time the 2.8 was observed. Then, 
CEA would classify this patient as positive at 2 of 5 non-progression visits £ind at the 
progression visit. See Figure 2.1 for a pictorial description. Open circles denote the 
non-progression visits and solid circle denotes the progression visits. For this patient 
we have two false positives, three true negatives and one true positive. 
0 Nonprqgtession 
• Progr^ion 
• 
0 
0 0 0 
1 2 3 4 5 6 
TIME 
Figure 2.1: Hypothetical example 
We would estimate the specificity, 
Pr{Marker negative \ gold standard negative) = 3/5 
and the sensitivity, 
Pr{Marker positive | gold standard positive) = 1.0. 
We can summarize the data from this patient with outcome vector as (3/5,5,1,1)', 
which we can view as «in observation of a random vector where 
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N2 represent the number of times the patient is a control (non-progression) or a case 
(progression), and F, H represent the patient's estimated specificity cind sensitivity. 
Generalizing the above problem and stating it using statistical terminology, let 
X^jjg be the continuous random variable whose observation is the ith marker, i = 
l,--',m, obtained from the jth patient, j = 1,•••,«, at the A:th non-progression 
evaluation, (determined by the gold standard (physical exam)), k = 
where iVjj is the number of non-progressions for patient j. Similarly, let Y^ji be 
the continuous random variable obtciined from the ith marker and the jth patient 
at the Ith. progression evaluation where I = 1, • • •, N2j and N2j is the number of 
progressions for patient j. Note that iVjy and are random. Moreover, we 
assume that Nij, j = 1, • • •, n are identically and independently distributed {i.i.d.) 
random variables and that , j = 1, • • •, n axe i.i.d. random variables. Let and 
Gi be the distribution functions of and Yiji- Also let c = (cj,...,cmY be the 
vector of m fixed cutoff points where Cj is the fixed cutoflT point of the ith marker. In 
accordance with the standard applications of the diagnostic markers we assume that 
if the value of X^jj^ or Y^ji exceed the cutoff point then the marker i will classify 
the patient as a progression at the k{orl) th evaluation. Then the specificity, and 
sensitivity of the ith marker are 
^i(s) 
and 
respectively. We can obtain a nonparametric estimate Fij{-) of i^j(.) from the jth 
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patient, namely 
1 ""y 
Fiji') KXijk < ')• 
"Ij k=\ 
Similaily, let 
1 
= aet 5; 
2; /=i 
be a nonpaxametric estimate of = 1 — Gj"(.) from the jth patient. We can now 
define a random vector for each patient j, as 
for j = These n vectors axe independently and identically distributed. 
We then define sample specificity Ff(Cj), and sample sensitivity estimates of 
i^j(cj) and Hi{cj) for marker i, as 
" W- . 
^iin) ~ S ^vir. (^•^) 
i=l ^j=l ^3 
sAh) = E v" %''=') (2-2) 
j=l -^j=l 
where the weights {WjiVj) are functions of iVjj, N2j, respectively. We considered 
two diflFerent weights. The first way is to combine patients by taking the number of 
controls aind cases that they each contribute into account. This would give different 
weights to each patients. In normal theory framework, when we compare two popu­
lations with the same variauice, the first weight would be something like pooling the 
sample variances to estimate the variance of the populations. The second weight is to 
combine the  pat ients  equal ly .  In  other  words ,  we can def ine  {Wj,Vj)  = iNi j ,N2j)  
or (W^-, Vj) = (/(iVjj), I{N2j)), where I{x) = 1 if x > 0 and 0 otherwise. We require 
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that Wj(Vj)  = 0 if Nij{N2j)  = 0, as F^j{Hij )  aire undefined if Nij{N2j)  = 0. Note 
that Fj(cj), and axe pooled estimates of and bcised upon all 
patients. 
In the next section, we will consider comparison of two markers at a fixed speci­
ficity. We will note here that the method is fairly flexible as it allows one to compare 
two different approaches to using the scime marker or to compare a combination of 
two markers to one of the markers. We will talk about these in detail in Chapter 4. 
2.3 Comparison of Two Markers 
2.3.1 Comparison At A Fixed Specificity 
We will obtain the asymptotic distributions of Fj(cj) and which will allow 
us to make inferences about the specificity and sensitivity, but first we consider the 
problem of comparing the difference in sensitivities at fixed specificity. We begin by 
setting the specificities of both markers equal to a fixed constant p, 0 < p < 1. In 
other words, we let Fj(cj) = p, i = 1,2. This yields Cj = F^~^(p) i = 1,2 and 
For aa estimate of Cj = {p) i = 1,2 we choose 
C£ =  inf ix  :  Fi{x)  > p}. (2.3) 
We assume that Nij;j = 1, • • •, n and the N2j'J = 1, • • •, w are bounded above by 
K. 
Theorem 2.1; Assume that and are twice differentiable at Cj with 
Fj(cj) = fiicj) > 0 and GJ (CJ) = 5j(cj) > 0, i = 1,2. Let n be the number of people 
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being followed and )C be the maximum possible number of evaluations per patient. 
Also let Fj(Cj) and as referred in (2.1) and (2.2), be the estimated specificity 
and sensitivity, respectively, for the ith marker and let C£ be the estimate of Cj given by 
(2.3), i = 1,2. Furthermore assume that 
E(9i(Nj j ) )  > 0 for i  = 1,2  where hounded non-negative functions 
satisfying ^(0) = 0. Then, 
asn oo where  A = H2i^) — -^1(^1) and A = ^^2(^2) ~ •^l('^l) 
nci,C2) = (7^)^ Var{Fi{ci ) )  + Var(F2(c2)) 
- \ -Var{Hi{c^))  + Var{H2{c2))  
-2Cav{Hi{ci ) ,H2{c2))  
+2 [Cm,(Fi(ci), H2M) - Co»(fi(ci),Hi(q))l 
+2 [Cov(f2(c2),^l(q)) - C^(F2(c2),H2i'=2))] 
d H ( x \  
and Hi{.) = 1 — Gj(.), and h^{x) = —, z = 1,2. We will now proceed with 
the proof of this theorem. 
Proof: Let's focus upon only one maxker, i.e., let X j f ^  F  and Yji  ^  G 
where for the jth person we have Nij noarecurrences (X's) and N2j recurrences 
(y's). Let 
n ly. 
Hc)= E 
jz=l ^J=l 
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1 be the pooled estimate of F(c) where Fj(c)  = 5Zjfc=i -  ^)- Similarly, let 
Mc) = E =5^flj(c) (2.4) 
i=l H=1 
1 ^2i be the pooled estimate of H{c)  = 1 — G(c) where Hj{c)  = ^O^j l  >  c) 
and (Wj ,Vj)  are defined as earlier. Also let c = in f{x  :  F(x)  > p} be the estimate 
of c = F~^(p). 
The outline of the proof is as follows. We begin by noting that 
m - Hie) = [(^(5) - Hie)) - iHie) - Hie))] 
+[Hi^-Hie)] + [Hie)-Hic)]. 
Next we will prove two lemmas to show that for the appropriate constants CQ and on 
|c - c| < CQ ilogn)^!'^, 
and that 
«<P|a_^|<„„ll(H(«) - H(c)) - (B(o) - /f(c))l| = 0(n-3/4 {.l09n)V'^) 
for sufficiently large n. Hence, using « when omitted terms are of lower order, 
V^{iy(c) - Hie)} « ^ /^^{F(c) - Hie) + V^{Hie) - Hie)}. 
Since 
Hie) - Hie) = (c - c)ft(c) + 0{(c - c)^} 
and wp 1, 
(c - c)/(c) = [F(c) - F(c) + 0{n-^l*{tognfl\ 
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as n —»• 00, we have 
-  B(c)} « ^ /S|-{4(c)//(c)}{f (c) - F(c)} + V5{a(c) - ^ (c)}. 
normal with meeui zero and some vaxiance V{c)  which will be defined later in detail. 
I will prove two lemmas. These lemmas are similar to those lemmas in Bahadur's 
(1966) paper which are outlined in details in Serfling (1980, pp. 94 - 96). 
Now we give the conditions under which c is contained in a small neighborhood 
of c for all sufficiently large n. 
Lemma I; Let 0 < p < 1. Suppose F is differentiable at c andF\c) = /(c) > 
0. Let W* = E(Wj) and assume that 0 < W* < K where K is a fixed bound such 
that K, > Tnax{Nij, N2j : j = !,•••,«). Then with probability 1 (wp 1) 
Proof (Lemma I): Since F is continuous at c with /(c) > 0, c is the unique 
solution of F{x—) <p< F{x) and F{c) = p. We will first show that for every e > 0 
( note £ may depend on n). 
We will then use the fact that for j = 1, • • •, n 
axe independent across patients and prove that y/n{H{c) — H{c)} is asymptotically 
for all sufficiently large n where CQ = 2/[f{c)]Cw] = JDI+ 
Pr{\c — cl > e) < 4exp{—2 n K-w^) 
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for all n where 8e = min{F{c + e) — p,p ~ F{c — e)) and Kw = (^+p)' 
we will use Borel-Cantelli lemma (Serfling, 1980, p.351) and put e = ^(/ogn) / ^ 
iCw f(c) •nM^ 
Write 
Pr(\c — c| > e) = Pr{c > c + e) -1- Pr{c < c — e). 
First consider 
n \Y-
Pr{c >c + e)  = Pr{Y,  ^  w  + £)<P) 
j=l ^j=l ^3 
n \Y- n 
j=lH=\^j  j=l  
+Pr( E (Wj -W*)>new) = A + B. 
j=l 
n n 
A=Pt(Y. 'w Fj (c + £) < P, E ^ " (W* + «<»)) 
j=l j=l 
^ - lWjFj(c  + c)  
= Pr(—^— < o) 
^  n { W * - \ - e w )  
E'l-iWjFjic + e) 
= Pr( x: 2i(c + e) > n + Cio) (1 - p)) 
3=1 
where Zj{c  + e)  = W* + Cw — W^" + Note that jE?(VI^- ^•(c + e)|Wy,iV2j) = 
Wj F(c + e) for all Wj, Nij. Hence 
A = + ^ ) - E + ^ )) > + e) - p) - npew)-
j=l j=l 
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Now let ew = ^ ~ where = F(c + e) — p. Then by 
Hoeffding's Lemma (see Lemma(HoefF<iing) in p.75 of Serfling(1980)) 
A=Pr{^ Zj{c+£)-  ^  E{Zj{c+e)) > ^  exp{-2n[^ (1+p)^ 
Now again by Hoeffding's Lemma 
« " W* o o 
B = PT (  £ Wj -  E B(Wj) >n€ W ) <  eip<-2n (^^(1+7)' 
This implies Pr(c > c + e) < 2exp(—2 n IC^ ^1^)- Similarly, Pr{c < c — e) < 
2exp(—2 n /C^ ^2^) where 82= p — F{c — e). Hence, 
Pr{\c — c| > e) < 4exp(—2 n /C^ Se^) (2.5) 
where Ss = T7iin{6i,62) and )Cw = ^ ~ ^ 
have 
= F{c + e) -  F{c) = /(c) e + 0(e) 
2{logn)^ f^  ^  { logn)^ l^  
~ — + > -TJ^ 
Zw Kw 
for all n sufficiently large and a similar relation holds for 62- Thus, for Se = 
nV2 ^1/2 
r
min{8\^82) we have 
2n 8^ > 2{logn) 
for all n sufficiently large. Hence by equation (2.5) we have 
Pr{\c — c] > e) < 4/n^ 
for all n sufficiently large n. By the Borel-Cantelli Lemma then wp 1 
\c-c\> e 
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hold for only finitely many n. 
In the next lemma we will show that 
5up{|[(^(c) - H{c))  -  {H{c)  -  H(c))]| : jc-cl < an]  = {logn)^!^) 
where an ~ eg n~^l^ {logn)^/'^ for some constant eg > 0. 
Lemma II: Let 0 < p < 1. Suppose that G is twice differentiable at c with 
G\C) = g{c) > 0. Then vop 1 
Hpn = st.p|j_^|<„„|[(a(c) - dW) - (Hie) - H(c))l| = 0(n-3/< (lognf/'^) 
asn OO where an ~ eg N~^l^  {LOGN)^!^ and CQ = ^ ^(c) Lemma L 
Proof (Lemma 11): Let {6n} be a sequence of positive integers such that 
6n ~ CQ n^l^{ logn)^ l^  
C\ 
as n —+ oo where en = ^ ri \ as in Lemma I. Let 
^ ICw /(c) 
Gnix)  = [{H{x)  -  H{c))  -  {H{x)  -  H{c))] .  (2.6) 
Let In = {c — an, c + an), an ~ eg {logn)^!^ as noo. Then 
Jlpn = •s«p{lGn(c)|: c G In}- (2.7) 
Consider a particulax n.  For integers r  = ~bn,  • • • ,bn,  le t  
Vr,n = c + 
ocr,n = H{rir,n) - ^('?r+l,n) 
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and 
Jr,n = [»7r,n,»7r+l,nl-
Note that 
In= U Jr,n-
\r\<bn 
Also note that if(.) = 1 — G(.) is monotonically decreasing. Hence for x 6 Jr,n 
•^('7r+l,n) ^ ^ HiVr,n) 
and 
H{r)r+l ,n)  ^ ^ •^('?r,n)-
Then from the definition of Gn for x G Jr,n 
Gnix)  < [H{vr ,n)  -  ^(c)]  -  [HiVr+l ,n)  "  ^ (c)!  
= Gnivr,!!) + ocr,n, 
and 
Gn(a:) > GniVr+l^n) ~ ^ r,n-
Thus, for X G Jr,n 
\Gn{x) \  <  max{\GniVr,n) \ ,  l(?n(»7r+l,n)l} + 
Then from (2.7) 
Hpn < max{\Gni.'nr,n)\ • r = -Wi, - • • ,bn} + '"iax{ar,n ' r = —bn,-'--,hn - 1} 
= Kn + ^n- (2-8) 
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By the mean value theorem for |r| < bn 
ar,n = H(T]r,n) -  •ff('7r+l,n) ^ ^n}iVr-\-l ,n " Vr,n) 
= sup{h{c): c G In} 
i.e., = 0{n~^l^). 
In view of (2.8), it will therefore suffice to show that if cj > 0 (to be chosen 
later) is sufficiently large, and if 7n = cj n~^l^{logn^l^, for n = 1,2, • • • then 
oo 
53 Pr{Kn >7n) <oo 
n=l 
or equivalently, 
oo 
£ ^K|Gn('7r,n)| > 7n) < CO. (2.9) 
n=l |rl<6n 
To establish (2.9) we will use the Bernstein inequality (Serfling (1980), p.95). 
Now let's consider jPr(IGn(f/r,n)l > In)- From (2.6) 
\Gn{r,r,n)\ = \{H{nr,n) - H{c)\ - [HM - i?(c)]| 
n V"- 1 -^2^ _ 
= l[ E s-n V N E  < y j l < c  +  n  ^  r ) ]  -  [ i / ( » 7 r , n )  -  i ^ ( c ) ] |  
j=l ^j=l V ^2j 1=1 
= I ^ - ^r,n\ 
j=l ^j=l 
for |r| < bn, and 6n ~ CQ where 
^2j 
t j ic)  = 5: /(c < Yji  < c + n-3/4 r)  
^ /=i 
= VjZjic) 
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and Zj{c) = -^(c < Yji < c+n ^/^r) and Zr,n = \G{c+n ^l^r)-G{c)\. 
Note 
•Pr(|Gn(j7r,n)| > 7n) = Pr{Gnivr,n) > In) + Pr(Gn(.Vr,n) < —fn)-
Consider Pr{Gn{-^r;n) > In)-
n t  -(c) 
Pr{Gnivr,n) > In) = Pr{ —V ~ ^ 
j=l ^j=l 
n 
i  P'i  E >m,T.Vj>n (y* -  £„)) 
j=l ^j=l ^7 i=l 
+Pr(f^ V-<n(V*-eti;)) 
J=1 
= 1 + 11 
where V* = E{Vj).  Then 
/  < Pri f ;  <j(c) >niV*- ew) {in + Zr,n))  
j=l 
= Pri E tj(c) -E{f2 ij i^))  >nV*in-new (7n + Zr,n)) .  (2-10) 
j=l j=l 
Let Cf and cr satisfy that 
where <7^ = Var{yjZj{c)) and 
(Tf <ct  an 
O 
cr^ > Set CQ. 
Since V* = £(Vj-) > 0 we can find a constant cv satisfying 
1 N ,1 
max(l, :^) < Cu < 1 + 
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Let cj = cr/[l — V*{cv — 1)]. Note that for fixed bound AC > max{Nij ,N2j :  j  = 
1, • •  •  ,n)  there exists  an N* such that  for n > N* 
22ia„l/4 ,^„-i/4 > 
Cr 3 
Let C2 be a constant such that C2 > $up{g{x),  x  6 In) for n > N* where g(.)  is the 
derivative of G(.). Then 
G{c + n~^^^r) — G{c) < sup{g{x),x € In)n~^/^r < C2CQn~^l '^{logn)^l^ 
for n large. We choose tw = {^<*9"") Note that 
C2 CQ +ci {logn)^/^ 
Zr,n ^ C2 an 
T" C]^ {logn)^/^ 
^ C2 cpn-V^ {logn)^!'^ ^ £2^/JL)l/4 
CI n-3/4 (/o5n)3/4 ~ q 
and 
From (2.10) 
Zr,n + In ^  ^ 2 + ci {logn)^!^ 
In d {logn)^!^ 
n n 
i  = MY. tj(c)-£(E 'jM) 
J=1 i=i 
" [in + Zr,n) c\  jV* Cy — 1) {logn)^!^ 
" C2Conl/4 +ci(/o5n)l/4 ^ 
< Pr( 53 <j(c) - •£( 7n - n 7n(V* Cu - 1)) 
i=l i=l 
n n 
= -PK S ^j(c)) > " 7n[l - - 1)]) 
i=i i=i 
n n 
= Pr( <j(c) - E{ fj-(c)) > ^ 7n) 
j=l j=l 
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= Pr{ E tjic)  -E{j:  tj ic))  > n Rn) 
3=1 J=1 
where Rn = crn~^^^{logn)^/^. A similar result will hold for 
^ ijic) t j ic))  < n Rn) 
j=l j=l 
and then using Bernstein's Theorem we get 
71 7Z 2 
Pri\  t j ic)  -E(J2 tj{c))\  >nRn)< ^ exp{- 2^(^x\rTi 
Now, 
nRn 
2 <7^ + (2/3) Rn 2a^ ^ ^2/s)K 
nRn nRn 
2c^cnn-l/2(/offn)l/2 2^„l/4(/o^„)-l/4 + (2/3)X: 
jRn V / ^ 
cr n Rn [logn)^!^ <^(logn) 
Acic^n)-!^ 4cfCo 
and hence 
> 2{logn).  
n  n 
Pr(| 53 ^ji^) ~ W)l > " -^n) < 4exp(—2(/o5fn)) = 4 n = 0(n" 
i=l i=l 
for |r| < bn and n > N*. Then in (2.9) we first get 
00 „ c» 
For //, recall 
Note that 
8 bnn ^ ^  Sn < 00. 
n=l n=l 
j=l 
, q (V* <V - l)((ojn)l/4 „,logn^^/^ 
02Conl/4+cinlM " 
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where D = • Then, by HoefFding's Lemma 
n2 (lo3risl/2 
II  < expi-2 n ) 
= ezp(— D* 
2 
where D* = ^^ 2' 
exp{— 
kl<6n 
Hence, 
C50 3 oo , . 
«=1 l'*l<6n «=1 |r|<6n ^=4 
3 oo n / J 1 /rt 
< 5 3  5 1  5 3  2 c o n ^ '  )  
n=l |r|<6n 
3 
< 53 53 L ^ coi^/^exp(—D* x^/^)dz 
'1=1 k|<6n 
and it can be shown that this integral is finite. Hence in (2.9) 
Pr(Kn >7n) = 0{n~^l^{logn)^l^)  
and in (2.8) this impKes that with probability 1 
Kn + 0n = 0{n~^l^{lognfl '^) ,  
as n goes to oo. 
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Note; Note that by using exactly the same arguments it can be shown that 
wp 1 
(«) - f W) - (f («) - f (c))] = 0(n-3/4 
as n —*• 00. 
Combining All The Results: Under the conditions of the theorem, ajid from 
lemma I, we have wp 1 that c —>• c. Then, wp 1 
F(c) - f (c) = /(c)(c - c) + - c)2 + o((c - c)2) 
= /(c)(c - c) + 0(n~^(lo^n)), (2.11) 
as n —+ 00. Combining Lemma I, the note of Lemma II, and equation (2.11) we get 
wp 1 
F(c) - F(c) = f(c){c - c) + 0{n~^l^{logn)^f^) 
ss n oo. Finally, we can show that wp 1, F{c) = F{c) + 0{n~^).  Recall that 
c = inf{x : F{x) > p}. Because of the continuity assumption (no ties), every time 
that  F has aui increase i t  occurs at  a  value for which a patient has a  marker since F 
is like a step function and has a jump (or increase) at each observation of the marker. 
Assume this increment is caused by j*th patient, then the size of the increment is 
Wj* 1 
If we choose Wj = Nij then this increment is 0(11n) since ^ » nW^ 
where 0 < W* < K. If we choose Wj = /(iVjj) then 
1 ^ 1  1  
Sj=l ^Ij > 0) 
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where Pr{Wj > 0) > 0 and increment is still 0(l/n).  Hence we have wp 1 
f (c) - F{c) = /(c)(c - c) + 0{n-^l^{lognfl\ (2.12) 
as n —» oo. Also, from Lemma II we have 
((f f(«) -  H(c)) -  (H{c) -  if(c))) = 0(n-'/'' ( . lognf 'h 
Again by Lemma I we have wp 1 that c —• c, we get 
ff(c) — H{c) = h{c){c — c) + 0{n~^{logn)).  
Now, writing (c — c) in terms of F ,  F from (2.12) we obtain wp 1 
H{c) -  H(c) = W -  fW) + 0(rr^lHtosnf ' '^)  
as n oo. So, wpl 
(H(c)  -  H(c) )  =  lA(c)  -  ff(c)l + l-^(f (c) - F(c) ) ]  
+[0(«-5/^((o9n)'/^)|. (2.13) 
We have shown that (f f ic)  — H(c)) is asymptotically equivalent to 
[A(c)-K(c)]-(|||(f(c)-f(c))l. 
The next step is to obtain the distribution of 
[ff(c) - H(c)] -  l^(Ac) - f (c))l-
To begin, we will define independently and identically distributed (i . i . d . )  vectors 
whose asymptotic distribution can be obtained via the multivariate central limit theo­
rem. We will then do a linear transformation of the components to obtain the desired 
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result. Recall that for each patient a random vector pj = {Fj{c),Nij,Hj{c),N2j) 
is obtained and pj, • * •,Pn are i.i.d. By definition 
t j ic)  = Wj Fjic) =  ^ i iNij)Fjic)  
for J = 1, • • •, R are also i . i .d.  Similarly, 
(J(c) = Vj Hj(c) = 92(N2j)Hj(c) 
for y = 1, • • •, n are i . i .d.  Hence if we let 
f 'j = (Jw, *2(%))' 
be a random vector for the jth patient then ^ i, • • • n " i . i .d.  random vectors 
with mean At' = {W* F{c),W*H{c\V*)' and variance-covariance matrix 
Var{tj{c))  Cov{tj{c),Wj) C<n}{tj{c), t ' -{c))  Cov{tj{c),Vj)  
.  Var{Wj) Cov{Wj,t ' j{c))  Cov{Wj,Vj)  
Var{tj(c))  Cov{t ' j(c) ,Vj)  
Var{Vj) 
Then from multivariate central limit theorem (Serfling (1980), p. 28), 
(2.14) 
J=1 
as n —^ CO, i.e., ^ ^ j  = M + Op(l/y/n).  At this time, we will try to write 
[ff(c) — ff(c)] and [F(c) — F(c)] as some linear combinations of ^ y, j = 1, • • •, n. To 
begin, we note that 
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and 
.-V,-
VJ 
«» / * 
are the ratios of two random variables where t j{c) = WjFj(c) £ind t j{c) = VjHj{c).  
We then expand these ratios about their expected vsJues in a Taylor series. For 
example, 
j=l j=l 
(see Fuller, 1976, chp. 5). Then 
MH(c) -  H{c) + Ao(F(c) - F(c))) 
= I :  < ; • ( ' ) + ^  I ;  ^  E  ' i  w  
"  j=i '  "  i=i '  "  j=i '  
+ Op(ll \ /n) li  • 4 J=1 
where AQ = -^1 = -^2 = -^3 = 4^' -^4 = ^ 
vector notation we then have 
VK{H(c) - H(c) + Ao(FW - f (c))) = v^(i E A ' « j + Op(l/\^)) 
J = 1 
where A '  = (•^, and XQ = Then from (2.14) 
"i=i 
as n —* oo.  It can be shown that X' n =0, and 
A ' E A = A§yar(F(c)) + Var{H{c)) + 2AoC<w(F(c), H{c)) 
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where 
-2^Co»((,-. »-,•), (2.15) 
Vcr{H(c)) = + (^fVaviyj)  
-2 
and 
Co»(f(o), ff(c)) = -  .I^Cov(tj ,  Vj)  
This then implies that in (2.13) 
MH{c)-H{c))-*N{0,V{c)) 
where 
y(c) = A ' S A 
= (^)2Var(f (c)) + Vcr(H(c)) -  2!^Cov(F{c),  H(c)).  (2.16) 
Finally, when we have two markers 
^W(c,)-A2(C2)-A) .  
\/n^ 
where A = ffj(ci) — H2{c2) and 
V(.ci ,C2) = (^)2 Var(f'i(ci)) + V<.r(F2{c2)) 
+Var(^l(q)) + Var(H2{c2)) 
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-2Cov{Hi{ci),H2{c2)) 
+2 [C<n7(fi(ci),ff2(c2)) - Cov(Fi(ci), ffiCq))] 
+2^^ [Co»(f2(c2),ffi(ci))-C»»(/'2(c2),a2(o2))l (2.17) 
/2(C2J 
which can be consistently estimated by method of moments. Note in this case we 
have 
((/iy(ci), F2j(c2)), Nij,  (Hijici) ,  H2j(c2% Nij) '  
T =r 1J  -  •  •  J n are i . i . d .  random vectors and we use a similar argument as above. 
2.3.1.1 Hypothesis Testing Proceeding with the theorem above, we now can 
test the following hypothesis 
^0 : A = 0 
where A = H2{p^~H\{ci). This hypothesis states that the two DMs have the same 
sensitivity at specificity p = Fj~^(ci) = F^^(c2). From Theorem 2.1, we proved 
that under 
V^(q7C2) 
as n —> oo. At this time an estimate of the variance term l^(cj,C2) is necessary. 
First, each of the terms in (2.15) can be estimated using the method of moments. 
For example, for Var{tj) and Cov{tj,Wj) the estimates would be 
Var{ t j )  =  
and 
C' o v ( t j ,  W j )  =  -  m .  
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respectively. Hence, an estimate of Var(F(c)) is 
V«r(f (c)) = + {^)hVar(Wj) 
-2^CMtrW^) 
where i — ^ ^ similar approach can be used for 
each of the terms Var{H^(c)},  Cov{F^{c) ,Hj{c)}.  An estimate of the variance term 
y(ci,c2) is obtained by substituting these estimates into (2.17). 
At fixed specificity p, we define the estimate of ki{c)l f i{c) to be 
[Hi{Fi-Hp + <)} - iti{F-Hp - «)}l/2< 
where 6 is mm[mm{p/3, (1 — p)/3},25/n] cind n is the number of patients. As a 
note, in our simulations we used min{p/Z,{l  — p)/3} since our s«imple sizes were 
only 30,50 and 100. Finally, Fi~^{p — S),  + 6) and c = F^^{p) must be 
estimated as well. We let c = F^^{p) = inf[x : > p), and define the estimates 
— 1 1 
of F- {p — S) and F- (p + ^ ) similarly. In all of the above computations, we then 
replace c by c. 
For two markers, say Maxkerl and Meirker2, examples of covaxiance terms ajre 
C<W(FI(ci),F2(<^2)) = ^Ccv<hi, t2j)  -
and 
Cov[HI(CI),H2(C2)) = 1 Vy) 
+ (2.18) 
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Again, each component of these terms can be estimated using the method of moments. 
At the end, we say that we have strong evidence ageunst Hr\ if ^ ^—- > z tn where 
^af2 (Q:/2)th percentile for the standard normal distribution. 
2.3.1.2 Confidence Intervals Recall that one of our goals was to construct 
confidence intervals for both the specificity eind the sensitivity. Since we have the 
explicit variance terms and their estimates available both for the specificity and the 
sensitivity ( see the previous subsection Hypothesis testing, and equation 2.15), we 
can easily construct a 100(l-a)% pointwise confidence interval for F as 
F±z^l2yIVaiiF) 
where ^^^2 (Q/2)th percentile for the standard normal distribution.The confi­
dence interval for sensitivity is analogous. 
2.4 Comparison of More Than Two Markers 
A generalization to the above set up is to test for the equality of the sensitivities 
of more than two markers. 
2.4.1 Comparison At A Fixed Specificity 
If we have k DMs, DMi,-• • testing the equality of sensitivities at a 
fixed specificity can be addressed by obtaining an estimate of the variance-covariance 
matrix, S, for {Hi (cj), ^ 2(^2)5' * * ? defining appropriate contrasts. For 
excimple, we can test 
Ho:Hi{ci)  = H2ic2) = --^Hk{ck) 
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versus H\ = HQ not true. By defining a (fc - 1) x fc matrix C as 
C = 
1 - 1  0  0  • • •  0  0  0  
0  1  - 1  0  • • •  0  0  0  
0 0 0 0 0 1 -1 
as the contrast, HQ cam then equivalently be written as HQ : C/JI = 0 where /t' = 
H2{c2), - • •, H}i.{c}g)y, is the vector of sensitivities. Then the statistic 
T2 = n{Cil /(CSC')-l(C/i ) 
will have a chi square distribution with (fc — 1) degrees of freedom (Johnson «ind 
Wichem, 1988, p.l45) and /2 = (Hi(cj),-",Hj^(cj^)/ is the estimates of sensitiv­
ities at fixed specificity and S is the vaxieince covariance matrix of /2 with entries 
Cov{H^{c^),Hj{cj)) (see 2.18). 
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CHAPTER 3. MONTE CARLO SIMULATION RESULTS 
3.1 Preliminaries 
In chapter 2, we developed statistics and studied their asymptotic behavior. To 
assess how our statistics axe applicable for a finite sample, we performed some sets 
of simulations and this chapter we present these results. 
3.2 Results For Fixed Specificity 
We present two sets of simulations. Both assume that the markers are normaJly 
distributed and the failure (progression) times axe exponentially distributed. In the 
first simulation, we based our theoretical pjirameters on the data obtained in the 
breast cancer study. In the second, we based our theoretical parameters on data 
obtained for an adjuvant colon cancer study not presented here in which the patients 
had a lower failure rate. The complexity of the simulation is due to the correlations 
within and between markers. To begin, we assumed that we had n independent 
individuaJs who had two markers XI and X2 obtained every month for a total 
of at most six visits per patient, i.e., Xi = (xil,• • • ,a:i6)', (i = 1,2). For each 
of the n patients, we generated three multivariate normal random vectors Zj = 
(zjj, • • •, ZIQY, i = 1,2,3, of size 6x1 with mean zero vector and variance-covaxiance 
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matrix 
S = 
'i- P P  ^ P  ^
1 p p^ 
• 1 P P" ^ 
. .  1 p p^ 
1 p 
. . . . 1 
where p is the fixed within marker correlation, i.e. the correlation between two 
consecutive observed values of the same marker on the same patient. 
We define the markers XI and X2 as 
XI = y/XZi + VT^Z2 
X2 = y/XZ^^ + y/l'—'XZ^ 
where A is the fixed between markers correlation. As seen in Figure 3.1, the per­
centage of breast cancer patients who are progression-free at six months is approx­
imately 30%. Hence, in our simiilations we generated failure times for patients 
as T — —A.98ln{U) where the Ws are pseudo-random deviates from a uniform 
(0,1) distribution. This results in exponential time to failure variables satisfying 
Pr{T > 6) = 0.3. 
For each patient we use the following method to determine the number of non-
progressions and progressions. If a failure time is greater than 6 months, we use 
the six values of XI and X2 for the patient and classify the patient as a control 
at all six visits. If a simulated failure time occurs before 6 months, we assume that 
the fciilure is detected clinically at the next visit. For example, if a failure occurs 
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0  1 2  3  
Years fram Randomization 
Figure 3.1: Survival rate for breeist cancer data 
between the third and fourth visit, the simulated markers for the first three visits 
use the values XI = (xll,xl2,xl3)' and X2 = (x21,a:22,x23)'while the markers at 
this fourth visit are obtained using the formulas Y1 = sl4 + m and Y2 = x24 + ^2 
respectively, where fi is the expected increase in marker value associated with being 
a failure (case). The patient is classified as a control at the first three visits and a 
case at the fourth visit. 
In our example we set n = 30,50, and 100 individuals with (/>, A) = (0,0) and 
(0.9,0.25). The last choice of (/), A) most closely matched the correlation in our breast 
cancer data. Tables 3.1 and 3.2 (in these tables correlated means p = 0.90, A = 0.25, 
and uncorrelated means p = 0.0, A = 0.0) show the proportion of times out of 1000 
simulations that 
^/n\h\ > l.%\jv{ci,c2) {for o. = 0.05) 
33 
ajid 
•\/n|A| > 1.645^V(CI,C2) { for  a  = 0.10) 
when A = 0 with both indicator weights {Wj,Vj)  = {I{Nij) ,I(N2j))  and pooled 
weights {Wj, Vj) = {Nij, N2j)- For the second set of simulations everything was the 
same except the visits were taken to be every six months and would have a progression 
rate of 50% at three ye<irs which more closely matches the colon cancer data. For zill 
of the above simulations, we let /i = 1 for both markers. 
Our conclusion from the above simulations is that the statistic performs well for 
sample sizes of 50 or more as nearly all the empirical rejection rates were within two 
standard deviations of the theoretical values (.05 and .10) for the 1000 simulations. 
This remained true in the presence of correlations within (repeated) markers and 
between markers. 
An issue of secondary interest was the effect on power of chcinging weight func­
tions for the statistic. One would anticipate that if there were no within (repeated) 
marker correlation, the weight function (Wj, Vj) = iNij,N2j) (referred to ais pooled 
weight in Table 3.3) would be optimal (since each observation is independent), but 
that as the correlation approached 1, the weight (Wj, Vj) = {I{Nij),I{N2j)) might 
be better .  In fact  if  the correlation was 1.0,  the weight {Wj,  Vj)  = {I{Nij) ,I{N2j))  
(referred to as indicator weight) would be optimal, since there would effectively be 
only one marker per patient. To obtain the entries in Table 3.3, we simulated data 
using the same parameters as in Table 3.1, except that we let ^2 = 1-77- (The choice 
of 1.77 was chosen to give us a power between 0.75 and 0.95 in Table 3.3). As cintic-
ipated the simulations resulted in higher power for the weight function {Wj,Vj)  = 
{Nij,N2j) when the correlation was 0 and for {Wj,Vj) = {I{Nij),I{N2j)) when 
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the correlation was 0.9. 
One would also anticipate that the power would be higher when there was a 
between marker correlation than when there was no such correlation, since we axe 
taking the pairing into account when computing the variance. This too was supported 
by the simulations. 
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Table 3.1: Rejection rates for six visits 
Weights(a) 
Breast Cancer Colon Cancer 
Sample Size Uncorr Corr Uncorr Corr 
Indicator(0.05) 
Indicator(O.lO) 
Pooled(0.05) 
PooIed(O.lO) 
n=30 
n=50 
n=100 
n=30 
n=50 
n=100 
n=30 
n=50 
n=100 
n=30 
n=50 
n=100 
0.072 
0.049 
0.045 
0.130 
0.094 
0.089 
0.068 
0.067 
0.053 
0.105 
0.126 
0.101 
0.047 
0.041 
0.053 
0.085 
0.090 
0.095 
0.061 
0.048 
0.052 
0.101 
0.094 
0.102 
0.056 
0.047 
0.050 
0.111 
0.094 
0.099 
0.057 
0.067 
0.065 
0.109 
0.112 
0.118 
0.049 
0.042 
0.045 
0.096 
0.089 
0.094 
0.057 
0.060 
0.053 
0.105 
0.099 
0.103 
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Table 3.2: Rejection rates for three visits 
Weights(Q:) 
Breast Cancer Colon Cancer 
Sajnple Size Uncorr Corr Uncorr Corr 
In<iicator(0.05) 
Indicator(O.lO) 
Pooled(0.05) 
Pooled(O.lO) 
n=30 
n=50 
n=100 
n=30 
n=50 
n=100 
n=30 
n=50 
n=100 
n=30 
n=50 
n=100 
0.063 
0.053 
0.054 
0.112 
0.105 
0.102 
0.070 
0.043 
0.048 
0.129 
0.093 
0.103 
0.065 
0.048 
0.060 
0.110 
0.093 
0.118 
0.070 
0.057 
0.061 
0.120 
0.111 
0.110 
0.063 
0.057 
0.053 
0.100 
0.108 
0.096 
0.063 
0.058 
0.049 
0.112 
0.095 
0.105 
0.053 
0.051 
0.037 
0.103 
0.092 
0.079 
0.062 
0.049 
0.055 
0.109 
0.094 
0.097 
37 
Table 3.3: Empirical significaDce levels 
p A Weight Power(5%) Power(10%) 
.0 .0 Indicator .82 .89 
.0 .25 Indicator .88 .93 
.9 .0 Indicator .83 .89 
.9 .25 Indicator .86 .92 
.0 .0 Pooled .83 .90 
.0 .25 Pooled .91 .94 
.9 .0 Pooled .77 .84 
.9 .25 Pooled .81 .89 
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CHAPTER 4. APPLICATIONS 
4.1 Description of The Clinical Study 
The North Central Cancer Treatment Group and Mayo Clinic recently completed 
a trial designed to permit an assessment of the role of six monoclonal antibodies, 
carcinoembryonic antigen (CEA), CA 19 — 9, OA 125, TPS, CA 72 — 4 and CA 
15 — 3 as markers for progression. All patients presented with breast cancer and had 
a lesion which was measurable or evaluable and could be followed for progression. 
The patients were all participants in a randomized trial which studied the efficacy of 
four chemotherapy treatment strategies. The study design and results of treatment 
strategies are discussed in Schaid et al, (1988) and Ingle et al, (1994). As part of 
the foUow-up, the patients were to report for a physical examination on a regular' 
schedule (every three-to-five weeks). During the physical examination blood was 
drawn and sent to a central pathology laboratory for analysis. When the blood was 
analyzed a numerical score was obtciined for each of the monoclonal antibodies. These 
scores were only available to personnel in the laboratory. In particular, the results 
were unknown to the treating physician and played no role in patient management. 
Conversely, patient characteristics and outcomes were unknown to the laboratory 
personnel. Over 95% of the patients in the study were followed to progression and 
the progression-free patients have at least three years of follow-up at this writing. 
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(See Figure 3.1) 
Repeated marker data were available &om 114 of the 226 brecist cancer patients 
who ha<i participated in the treatment tri<il. The treatment trial was underway when 
the maxker study was initiated, so some patients did not have the opportunity to 
participate in the marker trial. In other cases, markers were not sent in for logistic 
reasons. In a^ldition, there were periods when a particular assay was not available. 
Three msurkers of primary interest to the investigators were CEA, which was the 
standard marker at the initiation of the study, CA 15-3, and TPS. The latter two 
markers were new and had been very promising in pilot studies. Eighty-nine patients 
had, for each marker, a baseline value and at least one value obtciined during follow-
up. All the analyses in this manuscript will be from data pertaining to these patients 
and will be limited to the three markers of interest to the primary investigators. 
Forty-seven of the 89 patients had marker values at time of progression. 
4.2 Analyses of the Breast Cancer Data 
Although we ultimately analyze the breast cancer data using the notions of sen­
sitivity and specificity, we will first present analyses of the data using standard ap­
proaches. Since it will bring some insights about the prognostic value of the markers, 
we first analyze non-repeated breast cancer data, namely, the pretreatment marker 
values. Then, we will analyze the repeated mawker data using the time-dependent 
Cox model and end this section with analyses of the repeated marker data using the 
techniques we suggested in chapter 2. 
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4.2.1 Currently Available Methods 
We first wanted to see if the pre-treatment markers have prognostic values. For 
each marker (pre-treatment values of CA 153, CEA, and TPS), we divided the group 
of patients into quartiles with the first quartile being the patients with the lowest 
pre-treatment values, etc. We then compared the time to progression of patients by 
quaurtile using the logrank statistic (Kalbfleisch and Prentice, 1980, Lee, 1992). We 
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Figure 4.1: Kaplan and Meier survival curves for time to progression for 
pre-treatment CA 153. 
did not obtain any statistically significant differences. The time to progression curves 
for CA 153, CEA and TPS aie shown in Figures 4.1 to 4.3. Although there is 
some indication that the patients whose pre-treatment maxkers were in the lowest 
quartile did have the best prognosis, this is not as clear for CEA. We would conclude 
that association is not strong enough for the possibility of using these markers for 
determining treatments and/or monitoring options. At best, the maxkers might have 
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a role for stratifying patients on clinical studies. 
As we mentioned before, currently, the most accessible method for evaluating 
the repeated markers is to use a time-dependent Cox model (Cox, 1972). We used 
a time-dependent Cox model to test whether, at any point in time, the relative risk 
of progression for a patient with an elevated marker is greater than that of a person 
with a marker which is not elevated. We consider a marker to be positive if there is a 
50% increase in its current value to pre-treatment (or beiseline) value. In other words, 
the maxker value is considered positive if its current value is at least 1.5 times that 
of its baseline value. Note that we need to have a current value available to calculate 
the ratio to baseline and hence until the first post-treatment marker is observed we 
have no ratios. For example, suppose a patient has a pre-treatment CEA value of 1.6 
on the randomization date of August, 24, 1990. Her other marker values for CEA 
are 1.4 on September 17, 1990, 1.7 on October 8, 1990, 1.8 on October 29, 1990, 
1.6 on December 7, 1990, and lastly 1.6 on December 31, 1990. Also suppose this 
patient had a progression on December 31, 1990. Table 4.1 presents the intervals 
that we setup and the ratio to the baseline values for this patient. The results of the 
time-dependent Cox analyses for CA 153, CEA and TPS are shown in Table 4.2. In 
all cases there was an increase in risk associated with elevated markers. The most 
noticeable increase was seen in CA 153. For this marker the interpretation would be 
that there was a two-fold increase in the estimated relative risk for a patient when her 
current maxker was greater than 1.5 of its baseline vcilue and this result was highly 
statistically significant. 
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Figure 4.2: Kaplan and Meier survival curves for time to progression for 
pre-treatment CEA. 
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Figure 4.3: Kaplaui eind Meier survival curves for time to progression for 
pre-treatment TPS. 
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Table 4.1: Example for calculation of the ratio to bciseline values 
Calendar date Time interval (days) Ratio 
24AUG-17SEP [0,24) undefined 
17SEP-080CT (24-45) 0.8750 
080CT-290CT [45-66) 1.0625 
290CT-07DEC [66-105) 1.1250 
07DEC-31DEC [105-129) 1.0000 
31DEC-31.1DEC [129-129.1) 1.0000 
Table 4.2: Time-dependent Cox model (no adjustments on intervals) 
Markers Coefficient Risk Ratio P-value 95% C.I. 
CA 153 0.9131 
CEA 0.6089 
TPS 0.3633 
2.492 
1.838 
1.438 
0.0002 
0.0105 
0.1026 
(1.553,3.998) 
(1.153,2.930) 
(0.9296,2.224) 
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There were some patients who missed the scheduled three weeks visits. For 
example, there was a patient who has a baseline value on November 29,1989, and had 
two other visits on December 21,1989, and February 2,1990. Then she showed up on 
October 29, 1992 at which time she was found to have progression. For this patient 
we had intervals [21DEC89,02FEB90) and [02FEB90,290CT92). Note that the range 
of the second interval is almost 1000 days long. One might question the value of using 
a marker from nearly 1000 days earlier as a predictor so we did a second aji£ilysis 
in which we adjust the intervals in such a way that a marker value was accepted as 
reliable if it was obtained within 21 days of the current event. So, the above patient 
would have ratios defined in the following shorter intervals [21DEC89,10JAN91), 
[02FEB91,23FEB91) and in [10JAN91,02FEB91) and in [23FEB91,290CT92) the 
ratios would be undefined. The results from analyses using this modification are 
presented in Table 4.3. Again in all cases there seems to be an increase in risk 
associated with elevated markers. All results are significant. For CA 153 and CEA 
there is a two-fold increase in the estimated relative risk for a patient who has an 
50% increase from her baseline. 
These high relative risks strongly suggests that there is correlation between high 
marker values and disease progression. However, the relative risks do not help us 
much in determining whether markers are clinically useful or not. In the next section 
we will further examine the breast cancer data in terms of specificity and sensitivity 
as well as predictive values. 
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Table 4.3: Time-dependent Cox model (adjusted intervals) 
Markers CoeflScient Risk Ratio P-value 95% C.I. 
CA 153 0.8870 2.428 0.0003 (1.498,3.934) 
CEA 0.7482 2.113 0.002 (1.316,3.395) 
TPS 0.4427 1.557 0.0494 (1.001,2.421) 
4.2.2 Comparison At A Fixed Specificity 
There were several endpoints of interest to the primary investigators involved 
with this trial. The first one to be addressed in this section is the per visit specificity 
and sensitivity of the marker ais a predictor for a detectable progression at that visit. 
In this case, the result of the physical examination, progression or not, would define 
true positive or true negative. This is of particular interest if the ultimate goal is to 
use the marker as a substitute for a physical examination. Various modifications are 
of interest and will also be addressed in this study. For example, the marker may be 
replaced by the ratio of its value over a baseline or combined with ajiother marker. If 
we axe interested in using the marker as a predictor of progression, we may evaluate 
a marker according to what happens one month after it is observed. 
We would like to use our results to assist in providing further insight into the 
usefulness of the markers. The investigators had considered using the markers by 
classifying a patient as a progression whenever a mzirker had a value greater than 
1.5. When we use the definition given in Chapter 2, we find that our estimate of 
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specificity is 0.82 and of sensitivity is 0.30, implying that when a progression would 
first be detected by a clinical examination, there is only a 30% chance that the marker 
would have been positive. Conversely, if no clinical progression would have been 
identified at the visit, there is a 18% chance that the marker would have been positive 
anyway. Obtaining the empirical estimates of the variance of F{c) and G(c), we obtain 
95% confidence intervals for specificity and sensitivity of (0.74,0.89) and (0.17,0.43), 
respectively. The patients we studied had 354 visits without progression as opposed 
to 47 visits with progression. This would translate into a positive predictive value of 
only 18%. Thus, the marker would be of very limited value as a substitute for a clinical 
examination. We should note that since our markers had within marker correlations 
near 0.9, we used the weight (Wj,Vj) = {I{Nij),I{N2j)) in all computations. 
o. 
CO • O • 
02 03 1.0 0.4 0.6 0.0 
SpecHidty 
Figure 4.4: Sensitivity versus specificity curve for CEA, CA 15-3 «ind TPS for ratio 
over marker values using indicator weight. 
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Despite the somewhat disappointing findings described in the previous para­
graph, we were also interested in comparing the three markers to each other to see 
which markers might be most promising for further study. For illustrative purposes, 
we will let the value for each marker be its ratio (current value divided by baseline). 
Figure 4.4 is the plot of the sensitivity versus specificity across all cutoffs for each of 
the three antibodies. (As a note, ROC is the plot of sensitivity versus 1-specificity 
across all cutoffs.) The differences in our sensitivities are not significant between any 
of the markers for specificities of 0.80 or greater (which was the reinge of primary 
interest to the investigators), although the sensitivities for CA15-3 are significantly 
higher than for TPS at specificities 0.65 (p=0.05), 0.70 (p=0.01), and .75 (p=0.01). 
From these results ajid Figure 4.4, we would conclude that CA15-3 and CEA look 
more promising than TPS as markers, but that clear superiority for any marker has 
not been established. 
Since we chose to use the ratio of the markers to baseline rather than the actual 
value of the markers themselves, we thought it would be useful to see how the sen­
sitivities of the two approaches compared using CA15-3. We again define specificity 
and sensitivity as in Chapter 2, then plot the observed sensitivities and specificities 
of both possible markers (original value iind ratio) for all cutoffs (Figure 4.5). Notice 
that for the same specificities, the sensitivities are generally higher using the ratio 
than the original value. In fact, for all specificities between 0.65 and 0.85, application 
of our statistic shows these differences are significant. For example, at specificity 0.80 
the sensitivity of the ratio approach is 0.34 (using a cutoff of 1.46) while the sensitiv­
ity using the actual CA15-3 value (at a cutoff of 368) is 0.17 (p=0.02). Thus it does 
appear that the ratio of current value to baseline is a better marker than absolute 
48 
1.0 
03 
m 
s 
coO.4 
02 S_ I, ^1 
0.0 
0.0 0.2 0.4 0£ OS 1.0 
Specificity 
Figure 4.5: Sensitivity versus specificity curve for CA 15-3 original values versus 
CA15-3 ratio over marker values using indicator weight. 
value of the marker, at least for CA15-3. 
A final point of interest to the investigators was whether a marker might be 
useful in predicting progression shortly before the progression was to occur, rather 
than in having the marker ax:t as a substitute for a clinical examination. To address 
this, we modified our definitions of a case and control as follows. Eax:h time a patient 
had a marker, it was detennined whether or not the patient had a clinical evaluation 
1 week to 5 weeks after the marker was observed. If the patient did not have such 
an evaluation, the marker was not used in the analysis. If a patient did have one or 
more clinical evaluations 1 to 5 weeks later, we considered the patient to be a case for 
that marker if any of the clinical evaluations during the time period were positive and 
a control (no progression) otherwise. If a patient had a clinical progression within 
a week of when the marker was observed, we did not use the marker (since it was 
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taken too late to help initiate an intervention to prevent recurrence). The specificity-
sensitivity curves for this case are shown in Figure 4.6 for CA15-3 (original value 
ajid ratio). The results are disappointing, as the sensitivities are not significantly 
different from the values of (1-specificity) at any point, indicating that one would have 
a reasonable chance of producing such a specificity-sensitivity curve using random 
numbers. 
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Figure 4.6: Sensitivity versus specificity curve to predict progression for CA 15-3 
original values versus CA15-3 ratio over marker values using indicator 
weight. 
4.2.2.1 Comparison of MoreThsui Two Markers At A Fixed Specificity 
Recall that three markers of primary interest to us were CEA, CA 15-3, TPS. We saw 
that based on section 4.2.1 pdrwise comparison of three markers showed no significant 
differences at fixed specificity 0.8. Some investigators would advocate first performing 
a global testing for equality of the sensitivities of all three markers at fixed specificity 
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-S = 
n 
of 0.8. From the computer output estimate of the variance-covajiajice matrix for 
CEA, CA 15-3, TPS is 
0.004036 0.000785 0.000862 
0.004483 -0.000084 
0.002745 
with sensitivity estimates (0.319,0.340,0.213)'. Then from section 2.4.1, we obteiin 
C% 
T = 3.035, (p-value=0.219), indicating that there axe no significant differences 
among these three DMs. 
4.4 Discussion 
We have introduced a nonpaxametric approach to bringing concepts such as 
specificity and sensitivity into the analysis of repeated markers, since investigators 
suggested that they axe more comfortable with these concepts than relative risk, 
particularly when trying to determine how to implement potential markers in clinical 
practice. We found the concept to be useful in axialyzing the breast cancer data 
described above, although it was the unfortunate case that the markers all had rather 
poor sensitivities for specificities which would be of interest. This knowledge in itself 
was useful, since time dependent Cox Model an<ilyses identified a reasonably large 
relative risk (2.3) associated with high (ratio > 1.5) values of CA15-3. 
Our methods allowed for estimating the sensitivities and specificities, obtain­
ing confidence intervals for them, and compciring sensitivities at fixed specificities 
in the presence of the correlations introduced by the fact that markers may be ob­
tained £rom the same patient at multiple times and that more than one marker 
may be obtained from the same patient. The method is fjiirly flexible as it allows 
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one to compare two diiFerent approaches to using the saime marker or to compare 
a combination of two mairkers to one of the markers. For example, we could have 
compared  CA15-3  to  max[{CA\bZ  — min{CA\b  — 3)} / ran^e(CA15  — 3 ) ,  {CEA — 
min{CEA)  } / range{CEA)] .  
The statistic can e<isily be generalized to test for the equality of the sensitivity 
of more than two markers at a fixed specificity. 
A third generalization is to define a statistic for comparing sensitivities across a 
range of specificities, an approach we discuss in the next chapter. 
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CHAPTER 5. EXTENSION TO AREA 
5.1 Preliminaries 
We may be interested in the performance of a DM at all possible Veilues of cutoffs. 
This leads to the idea of so-c<illed ROC (Receiver (I prefer Relative) Operating 
Characteristic) curves (Swets and Pickett, 1982). An ROC curve is the trace of 
(1.0 - specificity, sensitivity) in the unit square. Wald (1950) introduced operating 
characteristic (OC) to the statistical decision theory. ROC, inspired by the OC idea, 
was developed in the context of signal detection theory (Green and Swets, 1966). The 
medical arena has benefited and used ROC analysis extensively since early 1980's. 
Swets (1979) and Metz (1978,1986) pioneered the application of ROC methodology 
in medical ajad raxliologic imaging. Recently, applications of ROC have been seen in 
a vciriety of branches of medicine. 
A generalization of interest for us is to define a statistic for comparing the sensi­
tivities across a range of all specificities, instead of being restricted to one specificity. 
A possible approach is to generalize Wieand, Gail, James and James (1989) which 
requires extending the results here for a fixed p over p 6 [0,1]. This is problematic 
since the statistic has such a complex covariance structure. Hence our approach was 
to first perform a simulation study to see if we could obtain reasonable estimates for 
the variance using bootstrap. In this chapter we will present the simulation results 
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of the area calculations. In section 5.2, we will describe the simulation cind bootstrap 
study and the results. In section 5.3 we discuss the application to breast cancer data 
and lastly, we will discuss our future approach. 
5.2 Simulations and Bootstrap Results 
In chapter 2, we provided adapted definitions of sensitivity and specificity for 
the repeated markers and in chapter 3, we described the simulation structure for a 
fixed specificity. We now want to see if we can estimate the variance of the area for 
a meurker using bootstraps. We begin by considering an example for which we know 
the theoretical results. We use the same strategy for the simulation designs as we 
did in chapter 3. 
We calculate the area under the sensitivity versus specificity curve by using the 
trapezoidal rule. We first assumed that the correlation within a patient to be zero. 
Using the result that the area under the curve is equal to Pr{Y > X) (Bamber, 1975), 
we  ca lcu la te  the  a reas .  Reca l l  i n  our  s imula t ions  Y ~ 7V(1 ,1 )  and  X ^  N{0 ,1 ) .  
Hence, if we use Wj = Nij as the weight 
Pr{Y  >X)  =  1 -  =  0.76025 
where $ is the stcindaxd normal distribution. Using this weight cind assuming no 
within marker correlation across visits, i.e., p = 0, it can be shown that asymptotic 
var i ance  i s  t he  same  as  fo r  t he  s ing le  marker  case  wi th  m = Ni j  and  n  =  
Under the independence and normality assumptions, DeLong, DeLong, and 
Clarke-Pearson (1988), and Wieand, Gail, and Hanley (1983) gives the variance of 
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the estimate of the area as 
Var(area) = (nm)~^(area[l — area]+ 
(m - l)(02l - (area)2) + (n - l)(0ii - (area)^)) 
where = Pr(Yi > ^"1,^2 > ^l) and ©21 = Pr{Yi > Xi,Yi > X2) and 
n and m are the number of cases (progressions) axid controls ( non-progressions), 
respectively. Note that ©jj and ©21 can easily be calculated from binormal distri­
bution and when we do the circulations we get ©11= ©21 ~ 0.6337. Next we try 
to calculate the expected number of cases and controls for our settings. We assume 
that the six months failure rate is 90%, so if we use 100 patients in our simulations 
we would expect 90 progressions. To determine expected number of controls we did 
the following simple procedure shown on Table 5.1. Using the exponentied failure 
probability, we calculated the the probability of having no progression at times 1 
month to 6 months. Then at each time point, expected number of cases and controls 
were calculated in a discrete manner, we assumed that we have 100 patients at time 
0 (beginning of the study). The probability of having no progression for a patient 
1 month later is 0.68. Hence we would expect 32 patients to be progressed and 68 
patients would be at risk. The probability of having no progression at the end of 2 
months is 0.46 and we would expect 46 patients to be at risk. We would also expect 
that all together 54 patients progressed at the end second month. Since 32 of these 
progressions are expected to occur at the end of the first month, we would expect only 
22 patients to progress between the first and second month. Similar calculations were 
performed for all 6 months. At the end we found the expected number of controls 
and cases to be 192 and 90, respectively. 
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Table 5.1: Expected number of cases «uid controls 
Month Pr(Success) Number of cases Number of controls 
1 0.68 32 68 
2 0.46 22 46 
3 0.32 14 32 
4 0.21 11 21 
5 0.15 6 15 
6 0.10 5 10 
Total 90 192 
With this information we calculated the theoretical asymptotic vaiiance of the 
area of one marker to be 0.000913. We then did 500 simulations with 200 bootstrap 
each. We aissimied that there were 100 patients in each of the simulations. We 
also assumed that there were two uncorrelated markers (i.e., A = 0). Out of 500 
simulations we obtain area estimates to be 0.7598, and 0.7600 for the two markers, 
respectively. The Monte Carlo simulation vcirieinces on the average were 0.001019 and 
0.0008617 for marker 1 and 2 respectively. From the bootstrap, the average variance 
of the difference in area was 0.0018285 and a 95% confidence interval for the bootstrap 
variance was (0.0017981,0.0018589) and the theoretical asymptotic variance for the 
area difference ( 0.001826) was well within the confidence interval. Note that the 
Monte Carlo simulation variance of the difference in area ( = 0.0018185) was also 
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well within the confidence interval. We also compared the distribution of the ratios 
of the difference in areas to its bootstrap standard deviation (I will «ill this the t-Iike 
statistic). For the above 500 simulations we obtained a normal probability plot for 
the t-like statistic and Figure 5.1 shows the graph. The slope of the line was 1.03 and 
the intercept was —0.02 which are estimates for the variance and mean, respectively. 
We concluded that there is a strong evidence that the asymptotic distribution is 
N(0,1) as we would hypothesize for the normality of the t-like statistic. 
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Figvire 5.1: Normal Q-Q plot of the ratio of the difference in area to its bootstrap 
standard deviation 
In the next set of simulations we used different combinations of p  and A with 
different weights. In these cases, no easy theoretical results were available and hence 
we compared the Monte Carlo variance to bootstrap variance and looked at the 
rejection rates. 
We used 50 and 100 patients and the number of times the absolute value of the 
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t-like statistic exceeds 1.645 and 1.96 is presented in Table 5.2. The resiilts are as 
we hoped and very promising. Note that in the Table 5.2, W^j = I{Nij) is called 
the indicator weight and Wij = iVjj is called the pooled weight. The variance of 
the area with the pooled weight is smaller thaai variance of the area with indicator 
weight (recall that there is no correlation). In all but two cases, the Monte Carlo 
variances were within two standard errors of the bootstrap variances. 
Table 5.2: Rejection rates for area 
Weights(a) Samiple Size Uncorr Corr 
Indicator(0.05) n=50 0.05 0.084 
p II o
 
o
 
0.054 0.045 
Indicator(O.lO) n=50 0.114 0.138 
n=100 0.092 0.121 
Pooled(0.05) n=50 0.044 0.082 
n=100 0.054 0.056 
Pooled(O.lO) n=50 0.096 0.142 
o
 
o
 
II a 0.106 0.094 
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Table 5.3 presents the simulated power results. In this case we used V ~ 
iV(1.65,1) and X ~ N(0,1) to get power between 0.77 and 0.98. The results are again 
very promising. As in the fixed specificity case one would expect that if there were 
no  wi th in  ( r epea ted)  marker  co r re la t ion ,  t he  we igh t  func t ion  {Wj ,V j )  =  {Ni j ,N2 j )  
(referred to as pooled weight in Table 5.3) would be optimal (since each observation 
i s  independen t ) ,  bu t  tha t  a s  the  cor re la t ion  approached  1 ,  the  we igh t  {Wj ,V j )  =  
{IiNij),I(N2j)) might be better. In fact if the correlation Wcis 1.0, the weight 
{Wj,Vj) = {I{Nij),I{N2j)) (referred to eis indicator weight) would be optimal, 
since there would effectively be only one marker per patient. As anticipated the 
s imtda t ions  r e su l t ed  in  h igher  power  fo r  t he  we igh t  func t ion  (Wj ,V j )  =  {Ni j ,N2 j )  
when the correlation was 0 and for {Wj, Vj) = (/(iVjj), /(-/V^^)) when the correlation 
was 0.9. 
One would also cuiticipate that the power would be higher when there was a 
between marker correlation than when there was no such correlation, since we are 
taking the pairing into account when computing the variance. This too was supported 
by the simulations. 
5.4 Applications to Breast Cancer Data 
Returning back to the breast cancer data, we calculated <ireas for CEA cind 
CA153. Recall that when we the compared CEA versus CA153 at a specificity of 0.8 
the normad score was -0.255 with two sided p-value of 0.7986. The estimate of the 
area tmder the curves are 0.600 and 0.620 for CEA and CA 153, respectively. The 
normeil score is -0.466 with two-sided p-value of 0.6412. Hence, there is little evidence 
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Table 5.3: Empirical significance levels for area 
p  A Weight Power(5%) Power(10%) 
.0 .0 Indicator .85 .91 
.0 .25 Indicator .90 .95 
.9 .0 Indicator .91 .96 
.9 .25 Indicator .97 .98 
.0 .0 Pooled .90 .96 
.0 .25 Pooled .96 .98 
.9 .0 Pooled .83 .90 
.9 .25 Pooled .86 .92 
of a difference in sensitivities between CEA and CA 153. 
5.5 Discussions 
In generalizing the fixed specificity results to compcire sensitivities ax;ross a range 
of or over all specificities we have considered theorems which are similar to results 
in Hajek and Sidak (1965, pp 180-181)). What we have tried can be summarized as 
follows. We first consider one mairker. Recall that in Chapter 2 we showed that at a 
fixed specificity, F(c) = p, 0 < p < 1, 
Tv{p)  =  V ^{H { c ) - H { c ) )  
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« v^(^(c) -  H{c))  -  (Mc)//(c))(F(c) - F(c)) -> Ar(0, V{c))  (6.1) 
where V{c)  is given in (2.16). To show the process Tv{ . )  converges to a Gaussiaji 
process Z{.), Hajek and SidaJc (1965, pp 180-181) require first that the finite dimen­
sional distributions of rt7(.) converges to comparable finite dimensional components 
of Z. For the 2-dimensional case, this would imply that for any finite constaints Aj 
and A2, and for any two specificities, F(cj) = pj, and F{c2) = P2J 
Ai7t;(pi) + A22\7(P2) 
converges to 
iV(0, Ai^VCcj) + X2MC2)  + 2XiX2Cov(Z(pi ) ,  Z(p2))), 
and secondly that for every e > 0, 
limg^QliminfvPr{max^^^_^^^^\Tv{pi) - Tv{P2)\ < e) = 1. 
The finite dimensional case will follow from reasoning presented in chapter 2, although 
it will require careful algebra. The heuristic idea for the two dimensional case follows: 
First we note that in (6.1) 
vW V- ' 
^=1 V 
and 
^ Wj • 
are the ratios of two random variables. As we did in chapter 2, we used the results 
that 
^1=1 Vj Wj 
-y  V* ,  • '  W*  
n n  
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and (6.1) can be rewritten as 
E?_i VzHAc) u(c\ n 
Tvir)« VS(( ' ' \ y , '  m)  -Me  (Vj  -  V*)) 
i=i 
Then, 
-^I^uCpi) + ^2^v{P2) ^ 
RRF\ TTF. \\ \ -^(^l) ^/T/ T/*\ 
•v/™('^l( — H{c i ) )  — Aj ~ ^ ) 
j= l  
hMXU^jFjM _  „ _ , Mai:fl£i) y w- _;v»)) 
/(q) nW* V(ci) nW^* ^ 
E?_i K-^,(C2) wrcol « 
+vi^ (^2( ' — MC2)) - T. fj - Y*) 
j= l  
,  Hc2) , ^ j ^ lWM)  , . Mc2) f (C2) ^ 
-*27( '^ •^<'2" - J?/ " "• ' ' 
Note here that for every patient j ,  j = 1, • • • ,n, we have n i.i.d. vectors 
(^j(q). fife). JVy. HjM,  ^ fe). ) 
and that all the terms in (6.2) are simple functions of components of the vectors 
so the asymptotic distribution of A]^rv(pi) + ^2^^iP2) obtciined using the 
multivariate central limit theorem. It can be shown that this will be as the cisymptotic 
distribution of XiZ{pi) + A2Z(p2)-
Thus far we have not been successful in showing tightness holds. The proof 
of tightness for most simple Brownian processes relies on transforming a vairiable 
62 
to a uniform distribution such that the probability of being between pj and P2 is 
Pi — P2 (Sen and Ghosh, 1971, pp. 193-194). The transformation which makes 
H{p) = GF~^(p) uniform is uniform over rather than p. This causes problems 
for p near 0 or 1 which we still need to address. 
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